These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 37196550)

  • 41. A multicenter phase 2 study of risk-adjusted salvage chemotherapy incorporating vinorelbine and gemcitabine for relapsed and refractory lymphoma.
    Pasricha SR; Grigg A; Catalano J; Leahy M; Underhill C; Arthur C; D'Rozario J; Lowenthal R; Reed K; Spencer A
    Cancer; 2008 Dec; 113(11):3192-8. PubMed ID: 18932253
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combination chemotherapy with gemcitabine and vinorelbine in the treatment of relapsed or refractory diffuse large B-cell lymphoma: a phase-II trial by the Hellenic Cooperative Oncology Group.
    Papageorgiou ES; Tsirigotis P; Dimopoulos M; Pavlidis N; Fountzilas G; Papageorgiou S; Economopoulos T;
    Eur J Haematol; 2005 Aug; 75(2):124-9. PubMed ID: 16000128
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer.
    Martoni A; Marino A; Sperandi F; Giaquinta S; Di Fabio F; Melotti B; Guaraldi M; Palomba G; Preti P; Petralia A; Artioli F; Picece V; Farris A; Mantovani L
    Eur J Cancer; 2005 Jan; 41(1):81-92. PubMed ID: 15617993
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomas.
    Wagner SM; Melchardt T; Egle A; Magnes T; Skrabs C; Staber P; Simonitsch-Klupp I; Panny M; Lehner B; Greil R; Keil F; Jäger U; Sillaber C
    Eur J Haematol; 2020 Mar; 104(3):251-258. PubMed ID: 31838747
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cisplatin, gemcitabine, and vinorelbine combination therapy in advanced non-small-cell lung cancer: a phase II randomized study of the Southern Italy Cooperative Oncology Group.
    Comella P; Frasci G; Panza N; Manzione L; Lorusso V; Di Rienzo G; Cioffi R; De Cataldis G; Maiorino L; Bilancia D; Nicolella G; Natale M; Carpagnano F; Pacilio C; De Lena M; Bianco A; Comella G
    J Clin Oncol; 1999 May; 17(5):1526-34. PubMed ID: 10334540
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Gemcitabine plus vinorelbine chemotherapy regimens: a pharmacokinetic study of alternate administration sequences.
    Cattel L; Airoldi M; Passera R; Cagliero E; Stella B; Goffredo F
    Pharm World Sci; 2004 Aug; 26(4):238-41. PubMed ID: 15446782
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Validated liquid chromatography-tandem mass spectrometry method for simultaneous quantitation of bendamustine and copanlisib in mouse plasma: Application to a pharmacokinetic study in mice.
    Tripathy HK; Manju SVN; Bestha RM; Kiran V; Dittakavi S; Mullangi R
    Biomed Chromatogr; 2022 Aug; 36(8):e5387. PubMed ID: 35470912
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Brentuximab vedotin followed by bendamustine supercharge for refractory or relapsed Hodgkin lymphoma.
    Picardi M; Della Pepa R; Giordano C; Pugliese N; Mortaruolo C; Trastulli F; Rascato MG; Cappuccio I; Raimondo M; Memoli M; Monteverde M; Mascolo M; Pane F
    Blood Adv; 2019 May; 3(9):1546-1552. PubMed ID: 31088808
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chemometric approach to open validation protocols: Prediction of validation parameters in multi-residue ultra-high performance liquid chromatography-tandem mass spectrometry methods.
    Alladio E; Pirro V; Salomone A; Vincenti M; Leardi R
    Anal Chim Acta; 2015 Jun; 878():78-86. PubMed ID: 26002328
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ultra-sensitive LC-MS/MS method for the quantification of gemcitabine and its metabolite 2',2'-difluorodeoxyuridine in human plasma for a microdose clinical trial.
    van Nuland M; Hillebrand MJX; Rosing H; Burgers JA; Schellens JHM; Beijnen JH
    J Pharm Biomed Anal; 2018 Mar; 151():25-31. PubMed ID: 29294409
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory hodgkin's lymphoma: experience with 27 patients.
    Zinzani PL; Vitolo U; Viviani S; Corradini P; Motta G; Tani M; Cascavilla N; Hohaus S; Merli F; Argnani L; Broccoli A
    Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):404-8. PubMed ID: 25840816
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes.
    Cheah CY; Chihara D; Horowitz S; Sevin A; Oki Y; Zhou S; Fowler NH; Romaguera JE; Turturro F; Hagemeister FB; Fayad LE; Wang M; Neelapu SS; Nastoupil LJ; Westin JR; Rodriguez MA; Samaniego F; Anderlini P; Nieto Y; Fanale MA
    Ann Oncol; 2016 Jul; 27(7):1317-23. PubMed ID: 27091808
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Development and validation of sensitive liquid chromatography/tandem mass spectrometry method for quantification of bendamustine in mouse brain tissue.
    He L; Grecula JC; Ling Y; Enzerra MD; Ammirati M; Kendra K; Cavaliere R; Mayr N; McGregor J; Olencki T; Mrozek E; Matharbootham M; Oluigbo C; Phelps MA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Sep; 905():141-4. PubMed ID: 22925718
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparative Chemometric Manipulations of UV-Spectrophotometric Data for the Efficient Resolution and Determination of Overlapping Signals of Cyclizine and Its Impurities in Its Pharmaceutical Preparations.
    Fares MY; Abdelwahab NS; Hegazy MA; Abdelrahman MM; El-Sayed GM
    J AOAC Int; 2022 Dec; 106(1):228-238. PubMed ID: 36124959
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Novel spectrophotometric and factor-based multivariate calibration-prediction techniques for determination of two inhibitors of hepatitis C-virus and hepatocellular carcinoma in pure, human urine, and human plasma.
    Zidan DW; Hassan WS; ElMasry MS; Shalaby AA
    Spectrochim Acta A Mol Biomol Spectrosc; 2019 Apr; 213():288-300. PubMed ID: 30708286
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.
    Bartlett NL; Niedzwiecki D; Johnson JL; Friedberg JW; Johnson KB; van Besien K; Zelenetz AD; Cheson BD; Canellos GP;
    Ann Oncol; 2007 Jun; 18(6):1071-9. PubMed ID: 17426059
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pilot study of an outpatient-based approach for advanced lymphoma using vinorelbine, gemcitabine and filgrastim.
    Spencer A; Reed K; Arthur C
    Intern Med J; 2007 Nov; 37(11):760-6. PubMed ID: 17542998
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bendamustine treatment in a heavily pretreated Hodgkin lymphoma patient.
    Elsoueidi R; Mulat A; Mourad H
    J Oncol Pharm Pract; 2014 Aug; 20(4):309-11. PubMed ID: 24847047
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
    Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Effective treatment with the additional administration of UFT for refractory malignant pleural effusion secondary to adenocarcinoma of the lung after the treatment regimen of gemcitabine and vinorelbine].
    Kawasaki Y; Koshohbu T; Nakatani S; Matsumoto S; Yasuda K; Hitsuda Y; Shimizu E
    Gan To Kagaku Ryoho; 2003 Jun; 30(6):845-8. PubMed ID: 12852354
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.